A carregar...
Publicação
A meta-analytic perspective on Arcobacter spp. antibiotic resistance
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 1.44 MB | Adobe PDF |
Orientador(es)
Resumo(s)
Objectives: Over the years, an increased prevalence of resistant strains of Arcobacter has been observed, which may be due to Arcobacter exposure to antibiotics used both in animal production and human medicine. A systematic review was performed with the objective of summarising the results of the rates of antimicrobial resistance of Arcobacter isolates.
Methods: The systematic review was performed according to PRISMA (Preferred Reported Items for Systematic Reviews and Meta-Analysis) recommendations, followed by meta-analysis.
Results: It was observed that the resistance rate ranged between 69.3-99.2% for penicillins and 30.5-97.4% for cephalosporins. The overall percentage of resistance to fluoroquinolones ranged from 4.3% to 14.0%, with the highest resistance percentage observed for levofloxacin. Resistance rates ranged between 10.7-39.8% for macrolides, 1.8-12.9% for aminoglycosides and 0.8-7.1% for tetracyclines.
Conclusions: These results show that Arcobacter spp. present resistance to various antibiotics commonly used and advocate further studies of the associated resistance mechanisms.
Highlights: First systematic review and meta-analysis evaluating resistance rates of Arcobacter spp; High resistance to β-lactams and low of resistance to aminoglycosides observed; Arcobacter spp. differ in rates of antimicrobial resistance.
Highlights: First systematic review and meta-analysis evaluating resistance rates of Arcobacter spp; High resistance to β-lactams and low of resistance to aminoglycosides observed; Arcobacter spp. differ in rates of antimicrobial resistance.
Descrição
Palavras-chave
Antimicrobial Resistance Arcobacter Meta-analysis Systematic Review Infecções Gastrointestinais
Contexto Educativo
Citação
J Glob Antimicrob Resist. 2019 Mar;16:130-139. doi: 10.1016/j.jgar.2018.12.018. Epub 2019 Jan 3. Review
Editora
Elsevier/ International Society for Chemotherapy of Infection and Cancer